---
title: "Vraylar (cariprazine), all indications: Specific populations questions"
description: "Specific populations questions on Vraylar (cariprazine) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Is Vraylar safe during pregnancy? Can Vraylar be taken while breastfeeding? Can elderly patients take Vraylar? Can Vraylar be used in patients with kidney impairment? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine), all indications: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)

## Pregnancy and breastfeeding

<a id="vraylar-pregnancy"></a>

### Is Vraylar safe during pregnancy?

> “Pregnancy Exposure Registry 
> There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to 
> VRAYLAR during pregnancy. For more information, contact the National Pregnancy Registry for 
> Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-
> programs/pregnancyregistry/. 
>
> Risk Summary 
> Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for 
> extrapyramidal and/or withdrawal symptoms following delivery (see Clinical Considerations). There are 
> no available data on VRAYLAR use in pregnant women to inform any drug-associated risks for birth 
> defects or miscarriage. The major active metabolite of cariprazine, DDCAR, has been detected in adult 
> patients up to 12 weeks after discontinuation of VRAYLAR [see Clinical Pharmacology (12.3)]. Based 
> on animal data, VRAYLAR may cause fetal harm.”

Source: [VRAYLAR: Prescribing information, page 26, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=26)

> “Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, 
> somnolence, respiratory distress, and feeding disorder have been reported in neonates whose mothers 
> were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have 
> varied in severity. Some neonates recovered within hours or days without specific treatment; others 
> required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms 
> and manage symptoms appropriately.”

Source: [VRAYLAR: Prescribing information, page 27, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=27)

<a id="vraylar-breastfeeding"></a>

### Can Vraylar be taken while breastfeeding?

> “Lactation studies have not been conducted to assess the presence of cariprazine in human milk, the 
> effects on the breastfed infant, or the effects on milk production. Cariprazine is present in rat milk. The 
> development and health benefits of breastfeeding should be considered along with the mother’s clinical 
> need for VRAYLAR and any potential adverse effects on the breastfed infant from VRAYLAR or from 
> the underlying maternal condition.”

Source: [VRAYLAR: Prescribing information, page 28, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=28)

## Specific populations

<a id="vraylar-elderly"></a>

### Can elderly patients take Vraylar?

> “Clinical trials of VRAYLAR did not include sufficient numbers of patients aged 65 and older to 
> determine whether or not they respond differently from younger patients. In general, dose selection for 
> an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the 
> greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other 
> drug therapy.  
>
> Antipsychotic drugs increase the risk of death in elderly patients with dementia-related psychosis. 
> VRAYLAR is not approved for the treatment of patients with dementia-related psychosis [see Boxed 
> Warning and Warnings and Precautions (5.1, 5.3)].”

Source: [VRAYLAR: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=29)

<a id="vraylar-kidney-impairment"></a>

### Can Vraylar be used in patients with kidney impairment?

> “No dosage adjustment for VRAYLAR is required in patients with mild to moderate (CrCL 
> ≥ 30 mL/minute) renal impairment [see Clinical Pharmacology (12.3)]. 
>
> Usage of VRAYLAR is not recommended in patients with severe renal impairment (CrCL 
> < 30 mL/minute). VRAYLAR has not been evaluated in this patient population.”

Source: [VRAYLAR: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=30)

<a id="vraylar-liver-impairment"></a>

### Can Vraylar be used in patients with liver impairment?

> “No dosage adjustment for VRAYLAR is required in patients with mild to moderate hepatic impairment 
> (Child-Pugh score between 5 and 9)”

Source: [VRAYLAR: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=29)

> “VRAYLAR is not recommended in patients with severe hepatic (Child-Pugh score 10–15) or renal impairment (creatinine clearance <30 mL/min), as it has not been evaluated in these patient populations<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=VRAYLAR%20is%20not%20recommended%20in,been%20evaluated%20in%20these%20patient)

> “Compared to healthy subjects, exposure (Cmax and AUC) in patients with either mild or moderate hepatic 
> impairment (Child-Pugh score between 5 and 9) was approximately 25% higher for cariprazine and 20% 
> to 30% lower for the major metabolites (DCAR and DDCAR) following daily doses of 0.5 mg 
> cariprazine for 14 days [see Use in Specific Populations (8.6)].”

Source: [VRAYLAR: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=33)

## Related pages
- [Medical information: Vraylar (cariprazine): All indications](https://www.evicenter.com/medical-information/vraylar)
- [Indication](https://www.evicenter.com/medical-information/vraylar/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vraylar/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/vraylar/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/vraylar/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vraylar/storage-and-supply)
